- Home
- PDC vs IOBT Comparison
PDC vs IOBT Comparison
Compare PDC & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PDC | IOBT |
|---|---|---|
| Founded | 2018 | 2014 |
| Country | Japan | Denmark |
| Employees | 20 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 12.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PDC | IOBT |
|---|---|---|
| Price | $7.00 | $0.04 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 111.6K | ★ 40.5M |
| Earning Date | 07-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $0.03 |
| 52 Week High | $7.90 | $2.79 |
Technical Indicators
Market Signals| Indicator | PDC | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 25.94 |
| Support Level | $3.99 | N/A |
| Resistance Level | N/A | $0.22 |
| Average True Range (ATR) | 0.86 | 0.02 |
| MACD | 0.22 | -0.01 |
| Stochastic Oscillator | 81.15 | 15.92 |
Price Performance
Historical ComparisonAbout PDC Perpetuals.com Ltd American Depositary Shares
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
About IOBT IO Biotech Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.